Physician profile
Brandon Vossen
NPI 1255988044
$530.92
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $113 · 2022: $418.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $174.39 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $76.99 | 2022 | |
| Glaxosmithkline, LLC. | $53.59 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $45.58 | 2021-2022 | |
| Grifols USA, LLC | $41.78 | 2022 | |
| Gilead Sciences, INC. | $26.52 | 2022 | |
| Endologix LLC | $22.19 | 2021 | |
| Janssen Pharmaceuticals, INC | $21.27 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.48 | 2022 | |
| United Therapeutics Corporation | $18.69 | 2021 | |
| Mallinckrodt Hospital Products INC. | $16.55 | 2022 | |
| Merck Sharp & Dohme LLC | $12.89 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Vossen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.